Review Proposes Mitochondria-Targeted CsA-TK-SS-31 (CTS) Micelle to Combat Alzheimer's Mitochondrial Dysfunction

<b>Alzheimer's disease (AD)</b> is a devastating neurodegenerative disorder characterized by progressive cognitive decline, for which current treatments offer only symptomatic relief. A critical, yet often undertreated, aspect of AD pathology is <b>mitochondrial dysfunction</b>. This cellular energy imbalance is strongly implicated in driving <b>neuroinflammation</b>, increasing <b>oxidative stress</b>, and ultimately leading to <b>synaptic dysfunction</b> and neuronal loss. The existing standard of care largely fails to address these fundamental mitochondrial deficits, highlighting a significant gap in therapeutic strategies. Understanding and targeting the intricate Metabolic–Mitochondrial–Inflammatory Feedback Loop is crucial for developing effective interventions that can halt or reverse AD progression.

This review systematically explores the multifaceted role of <b>mitochondrial dysfunction</b> in the initiation and progression of <b>Alzheimer's disease (AD)</b>. The authors synthesize current knowledge regarding how impaired mitochondrial function contributes to <b>neuroinflammation</b> and <b>cognitive impairment</b>. Furthermore, the work proposes a novel therapeutic strategy: the design of a <b>mitochondria-targeted micelle, CsA-TK-SS-31 (CTS)</b>. This micelle is conceptualized to deliver therapeutic agents, specifically Cyclosporine A (CsA) and the peptide SS-31 (elamipretide), directly to dysfunctional mitochondria within microglia and other brain cells, aiming to disrupt the self-reinforcing Metabolic–Mitochondrial–Inflammatory Feedback Loop implicated in AD pathogenesis.